GENITOPE BEGINS TRIAL OF MYVAX

Genitope has initiated a Phase I/II trial of MyVax, a personalized vaccine for chronic lymphocytic leukemia.

MyVax, which is tailored to the genetic makeup of each patient's own tumor, is intended to stimulate the patient's immune system to fight off the cancer.

The trial seeks to enroll approximately 70 adult CLL patients at nine North American cancer centers. The patients will be given 16 injections of MyVax over a one-year period.